# Obu Health reviews (2026): GLP-1 telehealth sellers | This GLP

The homepage card and the product tile print the same figure, which several sellers here cannot manage.

Publisher: This GLP Editorial Team
Canonical: https://thisglp.com/reviews/obu-health
Updated: 2026-10-28

By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Both pages agree

# Obu Health review

The homepage card and the product tile print the same figure, which several sellers here cannot manage.

## The verdict

Obu Health publishes starting figures of $190 a month for compounded semaglutide and $239 for tirzepatide. The homepage card and the product tile agree on both.

**Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures).

Category

GLP-1 telehealth

Molecule

Semaglutide · Tirzepatide

Form

Injection

From

From $190/mo

Prescription

Required

Compounded

Yes — not FDA-approved

Obu Health sells both molecules by injection. Two figures are published. Both use starting-from wording.

1.  ## Who writes the prescription, and what do they see?
    
    A prescription precedes shipping. The pages state prices. The clinician is not described and the intake is not documented.
    
    Agreement between two pages is a low bar and several sellers do not clear it. Obu does. What it does not do is say what raises the figure.
    
2.  ## What happens when the dose goes up?
    
    Nothing is published about dose. Starting from leaves the ceiling unstated. The floor is at least consistent across the site.
    
3.  ## What the price includes
    
    Six months at $190 is $1,140 and tirzepatide at $239 is $1,434, both at the floor. What a higher dose costs is not published. Ask before ordering.
    
4.  ## What it claims, and what it cites
    
    Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named.
    

## Where it holds up, and where it does not

-   Strength: Card and tile print the same figure
-   Strength: Both molecules carry a price
-   Strength: No fees described beside either
-   Limitation: Both figures are a floor
-   Limitation: No milligram dose stated
-   Limitation: No state coverage list is recorded
-   Limitation: No compounding pharmacy is named

## What the evidence says about this kind of treatment

The assessment above is about Obu Health. These are about the drugs it sells, and they are traced to the primary literature.

-   [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1)
-   [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1)
-   [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain)

Right for

A reader who values a site that agrees with itself.

Wrong for

A reader who needs a settled figure at their dose.

## The evidence behind what Obu Health prescribes

These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.

-   [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review)
    
    A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
    
-   [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better)
    
    In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
    

## How Obu Health compares

| Seller | Who it suits | Go |
| --- | --- | --- |
| NuDay Rx | Readers wanting an oral semaglutide at the injection price |  |
| Open Water Rx | Readers who want one all-inclusive figure with no code attached |  |
| PepHaūs | Readers who will commit a quarter for a modest saving |  |

[Compare all providers side by side →](https://thisglp.com/best)

More GLP-1 telehealth sellers reviews: [Telos Rx](https://thisglp.com/reviews/telos-rx) [The Aesthetic Concierge](https://thisglp.com/reviews/the-aesthetic-concierge) [The Edit](https://thisglp.com/reviews/the-edit) [The Virtual NP](https://thisglp.com/reviews/the-virtual-np) [TMates](https://thisglp.com/reviews/tmates) [TOM Weight Loss](https://thisglp.com/reviews/tom-weight-loss)

Sponsored alternative

SkinnyRx

Readers choosing tirzepatide, the one line with a published standing rate

## Frequently asked

Is $190 a rate?

It is a starting figure. What raises it is not published.

Do the two pages agree?

Yes. The homepage card and the product tile print the same figure on both lines.

What dose does it buy?

No milligram figure is published.

Is Obu Health expensive compared with other GLP-1 telehealth sellers?

Obu Health publishes a starting figure of $190/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Obu Health right at the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.

Or [compare every seller we cover](https://thisglp.com/best).

**Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).
